• English
  • Korean
  • Chinese
表紙
市場調査レポート - 63236

世界の幹細胞市場

The Global Market for Stem Cells

発行 BCC Research
出版日 ページ情報 英文 169 Pages
電子版即納可
価格
世界の幹細胞市場 The Global Market for Stem Cells
出版日: 2014年07月31日 ページ情報: 英文 169 Pages
担当者のコメント
米国の調査会社BCC Research社の発行です。前回の発行は2008年でしたので4年ぶりの改訂になります。治療法概要から特許、市場状況、参入企業等を包括的に纏めています。
概要

世界の幹細胞製品市場は、2013年に約56億米ドルとなりました。同市場は2013年から2018年の期間中、CAGR13.6%で拡大し、2018年に106億米ドルへ達すると予測されています。

当レポートでは、世界の幹細胞市場について調査し、幹細胞研究の見通し、主要国・地域における現在の市場規模と成長率、幹細胞を支える重要な技術のレビュー、幹細胞産業の性質と構造の分析、近年のM&A活動を含む主要企業のプロファイル、および国・主要治療分野別による今後5ヵ年の市場予測などを提供しています。

第1章 イントロダクション

第2章 サマリー

  • 定義
  • アプリケーション
  • 研究・商業化
  • 資金
  • 市場

第3章 概要

  • 細胞
  • 幹細胞

第4章 幹細胞研究

  • 歴史
  • 細胞ベースの治療
  • 幹細胞研究の規制
  • 幹細胞研究・製造の実用性
    • 幹細胞製造
    • 幹細胞獲得
    • 幹細胞製造のエコノミクス
    • 新しい幹細胞製造の発展
    • 分離・エンジニアリング
    • 幹細胞バンク
    • ISCBIプロジェクト

第5章 幹細胞のアプリケーション

  • 再生医療
  • 現在の幹細胞治療アプリケーション
    • 筋萎縮性側索硬化症(ALS)
    • パーキンソン病
    • 脊髄損傷
    • アルツハイマー病
    • 脳卒中
    • 心臓病
    • 末梢動脈疾患
    • 整形外科修復
    • 肝不全
    • 移植片対宿主病(GVHD)
    • 肺疾患
    • 幹細胞治験の状況

第6章 幹細胞の特許

  • 特許の一般的背景
  • 幹細胞の特許
  • 各国の政策
    • 米国
    • カナダ
    • 英国
    • ドイツ
    • 日本
    • 中国
    • iPS細胞

第7章 幹細胞市場

  • 幹細胞市場
    • 市場成長促進因子
    • 心疾患
    • 中枢神経系疾患
    • 糖尿病
    • 骨格系
  • 世界市場の推計・予測
  • 地域・国別の市場分析

第8章 企業プロファイル

第9章 付録1:用語

第10章 付録2:注目の幹細胞研究特許

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

BCC Research projects that the global stem cell market will grow from about $5.6 billion in 2013 to nearly $10.6 billion in 2018, registering a compound annual growth rate (CAGR) of 13.6% from 2013 through 2018.

This report provides:

  • An overview of the global market for stem cells and related technologies.
  • Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
  • Information on the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market.
  • Examination of strategies employed by companies specializing in this field to meet the challenges of a competitive and fast-growing market.
  • Comprehensive profiles of major players in the field.

image1

REPORT SCOPE

SCOPE OF REPORT

This report discusses the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting stem cells are reviewed, and the nature and structure of the stem cell industry is discussed with profiles of the leading companies, including recent M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.

ANALYST'S CREDENTIALS

Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the stem cell marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • MARKET ANALYSES AND FORECASTS
  • METHODOLOGY
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • DEFINITIONS
  • APPLICATIONS
  • RESEARCH AND COMMERCIALIZATION
  • FUNDING
  • MARKET
  • SUMMARY TABLE GLOBAL STEM CELL MARKET AND FORECASTS, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL STEM CELL MARKET AND FORECASTS, 2012-2018 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • CELLS
  • STEM CELLS
  • FIGURE 1 EARLY DEVELOPMENT OF EMBRYO
    • INDUCED PLURIPOTENT STEM CELLS
      • hpSCS
    • THE CANCER PROBLEM
    • CANCER STEM CELLS-A WIDER TOPIC

CHAPTER 4 STEM CELL RESEARCH

  • HISTORY
    • EMBRYONIC STEM CELLS
      • Growth and Identification of ESCs
      • Stimulating ESCs to Differentiate
    • NEW CELL LINE
    • ADULT STEM CELLS
      • Mesenchymal Stem Cells (MSCs)
      • Haematopoietic Stem Cells (HSCs)
      • Neural Stem Cells (NSCs)
      • Endothelial Progenitor Cells (EPCs) 2
      • Epithelial Stem Cells (ESCs)
      • Very Small Embryonic-Like Cells (VSELs)
    • CORD BLOOD STEM CELLS
    • INDUCED PLURIPOTENT STEM CELLS (IPSCS)
      • Nuclear Reprogramming
  • CELL-BASED THERAPEUTICS
    • EMBRYONIC-DERIVED STEM CELLS
    • ADULT/PROGENITOR-DERIVED STEM CELLS
    • ENGINEERED SCS FOR TRANSPLANTATION
    • THERAPEUTIC STEM CELL BANKING
    • STEM CELL-BASED BIOMEDICAL RESEARCH
    • TABLE 1 STEM CELL RESEARCH CENTERS
  • REGULATION OF STEM CELL RESEARCH
    • AUSTRALIA
    • BRAZIL
    • CANADA
    • CHINA
    • FRANCE
    • GERMANY
    • INDIA
    • IRELAND
    • ISRAEL
    • ITALY
    • JAPAN
    • SOUTH KOREA
    • SPAIN
    • SWEDEN
    • UNITED KINGDOM
    • UNITED STATES
      • California
      • Massachusetts
      • Michigan
      • New Jersey
      • New York
    • FDA APPROACH
    • EUROPEAN UNION
  • PRACTICALITIES OF STEM CELL RESEARCH AND PRODUCTION
    • STEM CELL PRODUCTION
    • STEM CELL ACQUISITION
      • Characterization and Expansion
      • Maintenance and Storage
    • STEM CELL PRODUCTION ECONOMICS
      • Customized Therapy
      • Banks
    • NOVEL STEM CELL PRODUCTION DEVELOPMENTS
    • ISOLATION AND ENGINEERING
      • Adult Stem Cells
      • Embryonic Stem Cells
      • Induced Pluripotent Stem Cells
    • STEM CELL BANKING
    • ISCBI PROJECT
    • TABLE 2 COUNTRIES ENGAGED IN THE ISCBI PROGRAM

CHAPTER 5 STEM CELL APPLICATIONS

  • REGENERATIVE MEDICINE
  • CURRENT APPLICATIONS OF STEM CELL THERAPY
    • CANCER
      • Hematopoiesis (Blood Cell Formation)
    • AMYOTROPHIC LATERAL SCLEROSIS
    • PARKINSON'S DISEASE
    • SPINAL CORD INJURY
    • ALZHEIMER'S DISEASE
    • STROKE
    • HEART DISEASE
      • Doubts Expressed
    • PERIPHERAL ARTERIAL DISEASE
    • TYPE 1 DIABETES
    • ORTHOPEDIC REPAIR
    • LIVER FAILURE
    • GRAFT-VERSUS-HOST DISEASE
    • LUNG DISEASE
    • STATUS OF STEM CELL CLINICAL TRIALS
      • Prochymal-stem Cell Therapy
        • Prochymal-Crohn's Disease and Gastrointestinal Injury from Radiation
      • Mesenchymal Precursor Cell (MPC) Product-Stem Cell Therapy (Orphan Drug)
      • MyoCell-Stem Cell Therapy
      • ixmyelocel-T-Stem Cell Therapy (Fast Track)
      • StemEx (carlecortemcel-L)-Stem Cell Therapy (Orphan Drug) (Fast Track)
      • GSK 2696273-Stem Cell Therapy
      • Adult Autologous Stem Cell Therapy (Renew)-Stem Cell Therapy

CHAPTER 6 STEM CELL PATENTS

  • GENERAL BACKGROUND ON PATENTS
  • STEM CELL PATENTS
    • PATENTABILITY OF STEM CELL LINES
  • INDIVIDUAL COUNTRY POLICIES
    • UNITED STATES
    • CANADA
      • EPC
    • UNITED KINGDOM
    • GERMANY
    • JAPAN
    • CHINA
    • iPS Cells
    • TABLE 3 IPS-RELATED PATENTS (YAMANAKA, 2011)
    • TABLE 4 CLASSIFICATION OF STEM CELL PATENTS

CHAPTER 7 STEM CELL MARKETS

  • MARKETS FOR STEM CELLS
    • MARKET DRIVERS
      • Healthcare
      • TABLE 5 HEALTHCARE SYSTEMS OF DIFFERENT COUNTRIES
      • Biotechnology
      • Pharmaceutical
      • MARKET OPPORTUNITIES BY THERAPEUTIC CLASS
    • CANCER
      • Other Cancers 8
    • CARDIOVASCULAR DISEASE
      • Myocardial Infarction
      • TABLE 6 EXAMPLES OF COMPANIES DEVELOPING STEM CELL THERAPIES FOR CVD
    • CENTRAL NERVOUS SYSTEM DISEASE
      • Spinal Cord Injury (SCI)
      • TABLE 7 STATISTICS FOR SCI WORLDWIDE, 2011
      • Neurodegenerative Diseases
      • TABLE 8 NEURODEGENERATIVE DISEASES WORLDWIDE, 2011 (MILLIONS)
    • DIABETES MELLITUS
    • TABLE 9 STATISTICS FOR DIABETES IN THE U.S., 2014
    • TABLE 10 GLOBAL MARKET FOR DIABETES MELLITUS TREATMENTS AND DEVICES, THROUGH 2018 ($ BILLIONS)
    • SKELETAL SYSTEM
  • GLOBAL MARKET ESTIMATES AND FORECASTS
  • TABLE 11 GLOBAL STEM CELL MARKET, THROUGH 2018 ($ MILLIONS)
  • REGIONAL AND NATIONAL MARKET ANALYSIS
    • AMERICAS
    • TABLE 12 AMERICAS STEM CELL MARKET, THROUGH 2018 ($ MILLIONS)
      • U.S.
      • TABLE 13 POTENTIAL U.S. PATIENT POPULATIONS FOR CELL-BASED THERAPIES
      • TABLE 14 THE U.S. STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 15 THE U.S. STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 16 THE U.S. STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • Canada
      • TABLE 17 CANADA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 18 CANADA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 19 CANADA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • Brazil
      • TABLE 20 BRAZIL'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 21 BRAZIL'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 22 BRAZIL'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • Mexico
      • TABLE 23 MEXICO'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 24 MEXICO'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
    • EUROPE
    • TABLE 25 EUROPEAN STEM CELL MARKET, THROUGH 2018 ($ MILLIONS)
      • Market Opportunities by Disease Category
      • TABLE 26 STATISTICS FOR CVD IN EUROPE, 2012
      • TABLE 27 RATE OF DEATH FROM HEART DISEASE IN DIFFERENT EUROPEAN COUNTRIES, 2012 (NO. OF DEATHS PER 100,000 CASES)
      • TABLE 28 STATISTICS FOR CNS DISORDERS AND INJURIES IN EUROPE, 2013
      • TABLE 29 STATISTICS FOR SCI AND PARKINSON'S DISEASE IN DIFFERENT EUROPEAN COUNTRIES, 2011
      • TABLE 30 PREVALENCE OF DIABETIC PATIENTS IN DIFFERENT EUROPEAN COUNTRIES, 2013
      • France
      • TABLE 31 FRANCE'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 32 FRANCE'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 33 FRANCE'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • Germany
      • TABLE 34 GERMANY'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 35 GERMANY'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 36 GERMANY'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • Italy
      • TABLE 37 ITALY'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 38 ITALY'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 39 ITALY'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • Spain
      • TABLE 40 SPAIN'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 41 SPAIN'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 42 SPAIN'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • United Kingdom
      • TABLE 43 U.K.'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 44 U.K.'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 45 U.K.'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
    • ASIA
      • Market Opportunities by Disease Category
      • TABLE 46 STATISTICS FOR CVD IN DIFFERENT REGIONS OF THE WORLD, 2011
      • TABLE 47 EXAMPLES OF STEM CELL POLICIES IN ASIAN COUNTRIES
      • TABLE 48 ASIA'S STEM CELL MARKET, THROUGH 2018 ($ MILLIONS)
      • Japan
      • TABLE 49 JAPAN'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 50 JAPAN'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 51 JAPAN'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • China
      • TABLE 52 CHINA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 53 CHINA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 54 CHINA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • India
      • TABLE 55 POTENTIAL CANDIDATES FOR STEM CELL THERAPY IN INDIA
      • TABLE 56 INDIA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 57 INDIA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 58 INDIA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
      • REST OF WORLD
      • TABLE 59 REST OF WORLD STEM CELL MARKET, THROUGH 2018 ($ MILLIONS)

CHAPTER 8 COMPANY PROFILES

  • 3DM
  • AASTROM BIOSCIENCES INC.
  • ADVANCED CELL TECHNOLOGY INC.
  • ALDAGEN INC.
  • ANGIOBLAST SYSTEMS
  • ARTERIOCYTE
  • ATHERSYS INC.
  • BEIKE BIOTECHNOLOGY CO., LTD.
  • BIOHEART INC.
  • BIOTIME INC.
  • BRAINSTORM CELL THERAPEUTICS INC.
  • CAPRICOR INC.
  • CARDIO3 BIOSCIENCES S.A.
  • CELLARTIS AB
  • CELLERANT THERAPEUTICS INC.
  • CELLERIX SA
  • CELLULAR DYNAMICS INTERNATIONAL
  • CYTORI THERAPEUTICS INC.
  • EPISTEM LTD.
  • FORTICELL BIOSCIENCE INC.
  • GAMIDA CELL, LTD.
  • GLOBALSTEM
  • HYBRID ORGAN GMBH
  • INTELLICELL BIOSCIENCES INC.
  • INTERNATIONAL STEM CELL CORP.
  • JUVENTAS THERAPEUTICS INC.
  • MEDISTEM INC.
  • MESOBLAST LTD.
  • NEOSTEM INC.
  • NEURALSTEM
  • NEUROGENERATION
  • OSIRIS THERAPEUTICS INC.
  • PHARMASTEM THERAPEUTICS INC.
  • PLUREON CORP.
  • PRIMEGEN BIOTECH LLC
  • RENEURON GROUP
  • RHINOCYTE INC.
  • STEM CELLS INC.
  • STEMCELL TECHNOLOGIES SARL
  • STEM CELL THERAPEUTICS CORP.
  • STEMEDICA CELL TECHNOLOGIES INC.
  • STEMINA BIOMARKER DISCOVERY INC.
  • STEMPEUTICS RESEARCH PVT. LTD.
  • TIGENIX NV 158
  • TRISTEM CORP.
  • VERASTEM INC.
  • VERISTEM TECHNOLOGIES
  • VIACYTE
  • VITRO DIAGNOSTICS INC.
  • WICELL RESEARCH INSTITUTE
  • XPAND BIOTECHNOLOGY BV

CHAPTER 9 APPENDIX 1: GLOSSARY

CHAPTER 10 APPENDIX 2: SIGNIFICANT STEM CELL RESEARCH PATENTS

  • TABLE 60 SIGNIFICANT STEM CELL RESEARCH PATENTS

LIST OF TABLES

  • SUMMARY TABLE GLOBAL STEM CELL MARKET AND FORECASTS, THROUGH 2018 ($ MILLIONS)
  • TABLE 1 STEM CELL RESEARCH CENTERS
  • TABLE 2 COUNTRIES ENGAGED IN THE ISCBI PROGRAM
  • TABLE 3 IPS-RELATED PATENTS (YAMANAKA, 2011)
  • TABLE 4 CLASSIFICATION OF STEM CELL PATENTS
  • TABLE 5 HEALTHCARE SYSTEMS OF DIFFERENT COUNTRIES
  • TABLE 6 EXAMPLES OF COMPANIES DEVELOPING STEM CELL THERAPIES FOR CVD
  • TABLE 7 STATISTICS FOR SCI WORLDWIDE, 2011
  • TABLE 8 NEURODEGENERATIVE DISEASES WORLDWIDE, 2011 (MILLIONS)
  • TABLE 9 STATISTICS FOR DIABETES IN THE U.S., 2014
  • TABLE 10 GLOBAL MARKET FOR DIABETES MELLITUS TREATMENTS AND DEVICES, THROUGH 2018 ($ BILLIONS)
  • TABLE 11 GLOBAL STEM CELL MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 12 AMERICAS STEM CELL MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 13 POTENTIAL U.S. PATIENT POPULATIONS FOR CELL-BASED THERAPIES
  • TABLE 14 THE U.S. STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 15 THE U.S. STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 16 THE U.S. STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 17 CANADA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 18 CANADA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 19 CANADA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 20 BRAZIL'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 21 BRAZIL'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 22 BRAZIL'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 23 MEXICO'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 24 MEXICO'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 25 EUROPEAN STEM CELL MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 26 STATISTICS FOR CVD IN EUROPE, 2012
  • TABLE 27 RATE OF DEATH FROM HEART DISEASE IN DIFFERENT EUROPEAN COUNTRIES, 2012 (NO. OF DEATHS PER 100,000 CASES)
  • TABLE 28 STATISTICS FOR CNS DISORDERS AND INJURIES IN EUROPE, 2013
  • TABLE 29 STATISTICS FOR SCI AND PARKINSON'S DISEASE IN DIFFERENT EUROPEAN COUNTRIES, 2011
  • TABLE 30 PREVALENCE OF DIABETIC PATIENTS IN DIFFERENT EUROPEAN COUNTRIES, 2013
  • TABLE 31 FRANCE'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 32 FRANCE'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 33 FRANCE'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 34 GERMANY'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 35 GERMANY'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 36 GERMANY'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 37 ITALY'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 38 ITALY'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 39 ITALY'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 40 SPAIN'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 41 SPAIN'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 42 SPAIN'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 43 U.K.'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 44 U.K.'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 45 U.K.'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 46 STATISTICS FOR CVD IN DIFFERENT REGIONS OF THE WORLD, 2011
  • TABLE 47 EXAMPLES OF STEM CELL POLICIES IN ASIAN COUNTRIES
  • TABLE 48 ASIA'S STEM CELL MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 49 JAPAN'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 50 JAPAN'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 51 JAPAN'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 52 CHINA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 53 CHINA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 54 CHINA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 55 POTENTIAL CANDIDATES FOR STEM CELL THERAPY IN INDIA
  • TABLE 56 INDIA'S STEM CELL THERAPY MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 57 INDIA'S STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 58 INDIA'S STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 59 REST OF WORLD STEM CELL MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 60 SIGNIFICANT STEM CELL RESEARCH PATENTS

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL STEM CELL MARKET AND FORECASTS, 2012-2018 ($ MILLIONS)
  • FIGURE 1 EARLY DEVELOPMENT OF EMBRYO
Back to Top